LEMTRADA Drug Profile
✉ Email this page to a colleague
Summary for Tradename: LEMTRADA
High Confidence Patents: | 0 |
Applicants: | 1 |
BLAs: | 1 |
Recent Clinical Trials: | See clinical trials for LEMTRADA |
Recent Clinical Trials for LEMTRADA
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
City of Hope Medical Center | Phase 1 |
M.D. Anderson Cancer Center | Phase 1 |
National Cancer Institute (NCI) | Phase 1 |
Pharmacology for LEMTRADA
Mechanism of Action | CD52-directed Antibody Interactions |
Established Pharmacologic Class | CD52-directed Cytolytic Antibody |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for LEMTRADA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for LEMTRADA Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2013-08-13 | Company disclosures |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2013-08-13 | Company disclosures |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2014-08-05 | Company disclosures |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2015-12-08 | Company disclosures |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for LEMTRADA Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2033-03-11 | Patent claims search |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2028-04-10 | Patent claims search |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2039-02-26 | Patent claims search |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | ⤷ Try for Free | 2033-02-08 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for LEMTRADA
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2300703 | ⤷ Try for Free |
European Patent Office | 2027872 | ⤷ Try for Free |
Japan | 2006160754 | ⤷ Try for Free |
Spain | 2159624 | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for LEMTRADA
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
SZ 32/2001 | Austria | ⤷ Try for Free | PRODUCT NAME: ALEMTUZUMAB |
132016000055697 | Italy | ⤷ Try for Free | PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916 |
C20160019 00200 | Estonia | ⤷ Try for Free | PRODUCT NAME: ALEMTUZUMAB;REG NO/DATE: EU/1/13/869 16.09.2013 |
132008901655480 | Italy | ⤷ Try for Free | PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for LEMTRADA (Alemtuzumab)
More… ↓